Response Prediction for Vandetanib Treatment in Recurrent Medullary Thyroid Carcinoma using F18-FDG PET
Introduction: Given its neuroendocrine origin, the prognosis of medullary thyroid carcinoma (MTC) remained poor in common chemotherapeutic approaches. However, the encouraging results of tyrosine kinase inhibitors (TKI) such as vandetanib emphasize the high demand for selecting appropriate candidates.
Aim(s): We aimed to elucidate the feasibility of response prediction using 18F-FDG PET imaging.
Materials and methods: 18 patients with advanced MTC receiving vandetanib (300 mg daily) were enrolled. A baseline 18F-FDG PET prior to TKI and an early follow-up PET scan (3 months after TKI initiation) were performed. Tumor progression was assessed every 3 months according to RECIST. The predictive ability for progression-free survival (PFS) was examined by investigating 18F-FDG maximum standardized uptake value in lymph node (SUV(LN)max) or visceral metastases (SUV(MTS)max) as well as by analyzing clinical parameters (RET mutation status).
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Werner R
To read the full abstract, please log into your ENETS Member account.